FierceBiotech 6. Jan. 2026 FDA cites severe liver injury risk, unclear benefit behind Sanofi's MS drug rejection
FierceBiotech 6. Jan. 2026 UK biotech eyes $1B deal to enable eye gene therapy to be delivered in doctors' offices
FierceBiotech 5. Jan. 2026 Biobeat Technologies drums up $50M for its cuffless blood pressure monitor
FierceBiotech 5. Jan. 2026 Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit
FierceBiotech 5. Jan. 2026 Abbott launches AI-based Libre Assist, its new in-app feature for meal planning
FierceBiotech 5. Jan. 2026 Cash-strapped TME Pharma loses partner, prompting eye drug strategy rethink
FierceBiotech 5. Jan. 2026 Insilico, fresh off its Hong Kong IPO, pens potential $888M cancer R&D pact with Servier
FierceBiotech 2. Jan. 2026 Cellular energy booster restores cognition in mice with advanced Alzheimer’s disease
FierceBiotech 2. Jan. 2026 NIH instability grows with exit of neuro director, leaving half of institutes under interim leadership
FierceBiotech 2. Jan. 2026 Sanofi, Corcept surprised by FDA rejections for MS, Cushing's syndrome drugs
FierceBiotech 2. Jan. 2026 Neuralink to kick-start 'high-volume production' of brain-computer interface devices, Elon Musk says
FierceBiotech 2. Jan. 2026 Neuro biotech Nido closes after phase 2 study fails to move needle in rare disease